Browse > Article
http://dx.doi.org/10.3857/roj.2018.00094

Single nucleotide polymorphism of GSTP1 and pathological complete response in locally advanced rectal cancer patients treated with neoadjuvant concomitant radiochemotherapy  

Nicosia, Luca (Department of Radiation Oncology, Sant'Andrea Hospital, Sapienza University of Rome)
Gentile, Giovanna (Department of Neuroscience, Mental Health and Sense Organs, Sapienza University of Rome)
Reverberi, Chiara (Department of Radiation Oncology, Sant'Andrea Hospital, Sapienza University of Rome)
Minniti, Giuseppe (Department of Neurological Sciences, IRCCS Neuromed)
Valeriani, Maurizio (Department of Radiation Oncology, Sant'Andrea Hospital, Sapienza University of Rome)
de Sanctis, Vitaliana (Department of Radiation Oncology, Sant'Andrea Hospital, Sapienza University of Rome)
Marinelli, Luca (Department of Radiation Oncology, Sant'Andrea Hospital, Sapienza University of Rome)
Cipolla, Fabiola (Department of Neuroscience, Mental Health and Sense Organs, Sapienza University of Rome)
de Luca, Ottavia (Department of Advanced Molecular Diagnostic, Sant'Andrea Hospital, Sapienza University of Rome)
Simmaco, Maurizio (Department of Neuroscience, Mental Health and Sense Organs, Sapienza University of Rome)
Osti, Mattia F. (Department of Radiation Oncology, Sant'Andrea Hospital, Sapienza University of Rome)
Publication Information
Radiation Oncology Journal / v.36, no.3, 2018 , pp. 218-226 More about this Journal
Abstract
Purpose: Standard treatment for locally advanced rectal cancer consists of neoadjuvant radiochemotherapy with concomitant fluoropyrimidine or oxaliplatin and surgery with curative intent. Pathological complete response has shown to be predictive for better outcome and survival; nevertheless there are no biological or genetic factors predictive for response to treatment. We explored the correlation between the single nucleotide polymorphisms (SNPs) GSTP1 (A313G) and XRCC1 (G28152A), and the pathological complete response and survival after neoadjuvant radiochemotherapy in locally advanced rectal cancer patients. Materials and Methods: Genotypes GSTP1 (A313G) and XRCC1 (G28152A) were determined by pyrosequencing technology in 80 patients affected by locally advanced rectal cancer. Results: The overall rate of pathological complete response in our study population was 18.75%. Patients homozygous AA for GSTP1 (A313G) presented a rate of pathological complete response of 26.6% as compared to 8.5% of the AG+GG population (p = 0.04). The heterozygous comparison (AA vs. AG) showed a significant difference in the rate of pathological complete response (26.6% vs. 6.8%; p = 0.034). GSTP1 AA+AG patients presented a 5- and 8-year cancer-specific survival longer than GSTP1 GG patients (87.7% and 83.3% vs. 44.4% and 44.4%, respectively) (p = 0.014). Overall survival showed only a trend toward significance in favor of the haplotypes GSTP1 AA+AG. No significant correlations were found for XRCC1 (G28152A). Conclusion: Our results suggest that GSTP1 (A313G) may predict a higher rate of pathological complete response after neoadjuvant radiochemotherapy and a better outcome, and should be considered in a more extensive analysis with the aim of personalization of radiation treatment.
Keywords
Rectal cancer; Radiochemotherapy; Single nucleotide polymorphism; Prognostic factor; Tumor response; Genetic marker;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Sweeney C, Nazar-Stewart V, Stapleton PL, Eaton DL, Vaughan TL. Glutathione S-transferase M1, T1, and P1 polymorphisms and survival among lung cancer patients. Cancer Epidemiol Biomarkers Prev 2003;12:527-33.
2 Mahimkar MB, Samant TA, Kannan S, Tulsulkar J, Pai PS, Anantharaman D. Polymorphisms in GSTM1 and XPD genes predict clinical outcome in advanced oral cancer patients treated with postoperative radiotherapy. Mol Carcinog 2012;51 Suppl 1:E94-103.
3 Cecchin E, Agostini M, Pucciarelli S, et al. Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy. Pharmacogenomics J 2011;11:214-26.
4 Au WW, Salama SA, Sierra-Torres CH. Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ Health Perspect 2003;111:1843-50.
5 Wang Y, Spitz MR, Zhu Y, Dong Q, Shete S, Wu X. From genotype to phenotype: correlating XRCC1 polymorphisms with mutagen sensitivity. DNA Repair (Amst) 2003;2:901-8.
6 Balboa E, Duran G, Lamas MJ, et al. Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response. Pharmacogenomics 2010;11:747-61.
7 Kim DY, Paek TY, Oh SY, et al. Pretreatment selection of regimen according to genetic analysis improves the efficacy of chemotherapy in the first line treatment of metastatic colorectal cancer. J Surg Oncol 2014;109:250-4.
8 Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin 2014;64:104-17.
9 Janjan NA, Khoo VS, Abbruzzese J, et al. Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys 1999;44:1027-38.
10 Kim JS, Kim JS, Cho MJ, Song KS, Yoon WH. Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2002;54:403-8.
11 Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997;15:2040-9.
12 Rodel C, Graeven U, Fietkau R, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2015;16:979-89.
13 Borchiellini D, Etienne-Grimaldi MC, Thariat J, Milano G. The impact of pharmacogenetics on radiation therapy outcome in cancer patients: a focus on DNA damage response genes. Cancer Treat Rev 2012;38:737-59.
14 Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006;93:1215-23.
15 Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010;11:835-44.
16 Smith JJ, Wasserman I, Milgrom SA, et al. Single nucleotide polymorphism $TGF{\beta}1$ R25P correlates with acute toxicity during neoadjuvant chemoradiotherapy in rectal cancer patients. Int J Radiat Oncol Biol Phys 2017;97:924-30.
17 Osti MF, Nicosia L, Agolli L, et al. Potential role of single nucleotide polymorphisms of XRCC1, XRCC3, and RAD51 in predicting acute toxicity in rectal cancer patients treated with preoperative radiochemotherapy. Am J Clin Oncol 2017;40:535-42.
18 Zhang H, Wang M, Shi T, et al. TNF rs1799964 as a predictive factor of acute toxicities in Chinese rectal cancer patients treated with chemoradiotherapy. Medicine (Baltimore) 2015;94:e1955.
19 Agostini M, Pasetto LM, Pucciarelli S, et al. Glutathione S-transferase P1 Ile105Val polymorphism is associated with haematological toxicity in elderly rectal cancer patients receiving preoperative chemoradiotherapy. Drugs Aging 2008;25:531-9.
20 Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006;355:1114-23.
21 Losi L, Luppi G, Gavioli M, et al. Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapy. Int J Colorectal Dis 2006;21:645-51.
22 Mandola MV, Stoehlmacher J, Muller-Weeks S, et al. A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 2003;63:2898-904.
23 Bohanes P, Rankin CJ, Blanke CD, et al. Pharmacogenetic analysis of INT 0144 Trial: association of polymorphisms with survival and toxicity in rectal cancer patients treated with 5-FU and radiation. Clin Cancer Res 2015;21:1583-90.
24 Paez D, Salazar J, Pare L, et al. Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes. Int J Radiat Oncol Biol Phys 2011;81:1319-27.
25 Harries LW, Stubbins MJ, Forman D, Howard GC, Wolf CR. Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 1997;18:641-4.
26 Damaraju S, Murray D, Dufour J, et al. Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer. Clin Cancer Res 2006;12:2545-54.
27 Edvardsen H, Kristensen VN, Grenaker Alnaes GI, et al. Germline glutathione S-transferase variants in breast cancer: relation to diagnosis and cutaneous long-term adverse effects after two fractionation patterns of radiotherapy. Int J Radiat Oncol Biol Phys 2007;67:1163-71.
28 Watson MA, Stewart RK, Smith GB, Massey TE, Bell DA. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 1998;19:275-80.
29 Di Simone D, Galimberti S, Mattii L, Petrini M. c-Jun and GST-pi expression in human plasma cells. Haematologica 1997;82:69-70.
30 Srivastava SK, Singhal SS, Hu X, Awasthi YC, Zimniak P, Singh SV. Differential catalytic efficiency of allelic variants of human glutathione S-transferase Pi in catalyzing the glutathione conjugation of thiotepa. Arch Biochem Biophys 1999;366:89-94.
31 Wang J, Jiang J, Zhao Y, et al. Genetic polymorphisms of glutathione S-transferase genes and susceptibility to colorectal cancer: a case-control study in an Indian population. Cancer Epidemiol 2011;35:66-72.
32 Ates NA, Tamer L, Ates C, et al. Glutathione S-transferase M1, T1, P1 genotypes and risk for development of colorectal cancer. Biochem Genet 2005;43:149-63.
33 Kitade H, Shimasaki T, Igarashi S, et al. Long-term administration and efficacy of oxaliplatin with no neurotoxicity in a patient with rectal cancer: association between neurotoxicity and the GSTP1 polymorphism. Oncol Lett 2014;7:1499-502.
34 Abbas M, Kushwaha VS, Srivastava K, Banerjee M. Glutathione S-transferase gene polymorphisms and treatment outcome in cervical cancer patients under concomitant chemoradiation. PLoS One 2015;10:e0142501.
35 Okcu MF, Selvan M, Wang LE, et al. Glutathione S-transferase polymorphisms and survival in primary malignant glioma. Clin Cancer Res 2004;10:2618-25.